Magazine Article | June 1, 2023

Strategizing The Scale-Up Of Cell Therapy Manufacturing Capacity

Source: Life Science Leader

By Michelle Raley

Adaptimmune is one of the only cell therapy companies that has built an entire in-house manufacturing facility.

Mike Blankenstein, VP of patient supply operations, has been with the company for nearly five years, after 25 years of manufacturing and supply chain experience in a variety of industries. He provides strategic direction, leadership, and oversight of clinical and commercial supply planning and materials management for Adaptimmune’s global manufacturing and patient supply. Below, he discusses the company’s strategy for its cell therapy manufacturing facility and scaling up capacity.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader